Press Room

News / Mar 04, 2020

Hovione scholarship program supports four students from IST

Hovione renews the scholarship of three students and extended the support to one student

Hovione scholarship program supports four students from IST | Hovione
The students with Hélder Delgado, Sustainability Specialist at Hovione.

Hovione renews the scholarship of three students and extends the support to one student, all from the Instituto Superior Técnico (IST). The ceremony took place on Tuesday, 3rd March. Hovione’s scholarship program – “Hovione Solidária na Educação” – will continue to support Ricardo Dias, Beatriz Colaço and Ana Oliveira (Chemical engineering students) and will extend the support to Mariana Carreira Bento (Biomedical engineering student).

“These scholarships are a way of expressing our gratitude to the universities that produce the most employable graduates and also a way of supporting students with outstanding academic merit who need financial aid”. Hélder Delgado gave an example of a former scholarship recipient from Técnico who is currently working at Hovione and expressed his wish that what has happened before may happen again with these students. “We want to turn this support into useful relationships between our company and students”.

 

Read the entire article on IST's website

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026